CR

Critical Reviews In Oncology Hematology

Critical Reviews in Oncology/Hematology is the official journal of the European School of Oncology and the International Society of Liquid Biopsy. It publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world, covering themes including basic experimental oncology, clinical research, hematology, immunotherapy, molecular pathology, genomics and omics, liquid biopsy, pediatric oncology, radiotherapy, surgery, palliative support, and health policy.

Looking to publish in Critical Reviews In Oncology Hematology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Hematology, Oncology
Impact Factor 5.6
Quartile Q1
Open Access Type Hybrid
ISSN 1040-8428
eISSN 1879-0461
Invitation Only No
Cost Range Open Access APC: USD 4,180 (excluding taxes); subscription: no publication fee charged to authors.

Submission Instructions

Critical Reviews In Oncology Hematology accepts the following article types. Click on an article type to view submission instructions.

Review Articles

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract is required. Abstract must not exceed 250 words. Abstract must be unstructured.
Manuscript Manuscript should not exceed 8,000 words excluding tables and figures. Manuscript must be divided into clearly defined numbered sections and include a Critical View section at the end of the review. Submission must include 1 to 7 English keywords, 3 to 5 article highlights submitted separately, and any AI or AI-assisted tool use in the research design or methods must be disclosed reproducibly in the methods section.
References A maximum of 100 references is recommended, with exceptions possible subject to editor approval. Reference list must be arranged alphabetically and then chronologically if necessary, with same-year works by the same author distinguished by letters.
Figures & Tables Review Articles should not exceed 6 figures and/or tables. Tables must be placed next to the relevant text or on separate pages at the end of the article, and figures must be supplied as separate files. Tables must be editable text with captions and figures must each have a caption.
Reformat to Critical Reviews In Oncology Hematology using Livewrite Premium

Recent Publications

Personalized neoantigen cancer vaccines: Why clinical benefit remains inconsistent

Shishir Singh, Monisha Banerjee, Atar Singh Kushwah

10.1016/j.critrevonc.2026.105336
View Publication

Human endogenous retroviruses in liver cancer: A double-edged sword in tumor progression and anti-tumor immunity

Xin Jiang, Zhen Huang, Yang Zhong, Wei Lv, Ruilong Zhou, Jianmin Wang, Jingfeng Liu

10.1016/j.critrevonc.2026.105337
View Publication

Alternative splicing of immune checkpoints: Classifications, mechanisms, and therapeutic implications for overcoming immune checkpoint blockade resistance

Ping Lu, Jihua Guo, Rong Jia

10.1016/j.critrevonc.2026.105339
View Publication

The dichotomous function of eicosanoid signaling in the pathogenesis and therapeutic management of lung cancer

Woo Hyun Park

10.1016/j.critrevonc.2026.105338
View Publication

Mapping the immune microenvironment of non-small cell lung cancer

Xinyue Ge, Mingtong Cai, Jiayi Nie, Linfeng Wang, Yue Li, Yue Hu, Jiaqi Meng, Hongyuan Liu, Liang Geng, Baojin Hua, Rui Liu

10.1016/j.critrevonc.2026.105335
View Publication

Frequently asked questions

How long does it take to publish?

7 days submission to first decision; 27 days submission to decision after review; 69 days submission to acceptance; 2 days from acceptance to first online publication.

Reformat to Critical Reviews In Oncology Hematology using Livewrite Premium

What are the publication costs?

Open Access APC: USD 4,180 (excluding taxes); subscription: no publication fee charged to authors.

Reformat to Critical Reviews In Oncology Hematology using Livewrite Premium

Research Topics

Lung Cancer Treatments and Mutations Diverse Scientific and Economic Studies Cancer Immunotherapy and Biomarkers Human auditory perception and evaluation Educational Robotics and Engineering Colorectal Cancer Treatments and Studies Cancer Genomics and Diagnostics Lymphoma Diagnosis and Treatment Cancer Treatment and Pharmacology Lung Cancer Research Studies Breast Cancer Treatment Studies Immunotherapy and Immune Responses HER2/EGFR in Cancer Research Frailty in Older Adults Prostate Cancer Treatment and Research CAR-T cell therapy research Chronic Lymphocytic Leukemia Research Cancer survivorship and care Acute Myeloid Leukemia Research Pancreatic and Hepatic Oncology Research Ovarian cancer diagnosis and treatment Glioma Diagnosis and Treatment Gastric Cancer Management and Outcomes Cancer Cells and Metastasis Head and Neck Cancer Studies